Brookline Capital Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital analyst Tyler Bussian initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and a price target of $10.
April 05, 2024 | 8:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Brookline Capital initiates coverage on Immunic with a Buy rating and a price target of $10.
The initiation of coverage by Brookline Capital with a Buy rating and a specific price target of $10 is a positive signal for Immunic. It suggests confidence in the company's future performance and potential for stock price appreciation. This can attract investor attention and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100